


































hJournal of Steroid Biochemistry & Molecular Biology 133 (2013) 12–24
Contents lists available at SciVerse ScienceDirect
Journal of Steroid Biochemistry and Molecular Biology
journa l homepage: www.e lsev ier .com/ locate / j sbmb
ifferences in transcriptional effects of 1,25 dihydroxyvitamin D3 on ﬁbroblasts
ssociated to breast carcinomas and from paired normal breast tissues
aura Tojeiro Camposa,1, Helena Brentanib,1, Rosimeire Aparecida Roelaa,1,
aria Lucia Hirata Katayamaa,1, Leandro Limac, Cíntia Flores Rolimd, Cíntia Milania,
aria Aparecida Azevedo Koike Folgueiraa, Maria Mitzi Brentania,∗
Departamento de Radiologia e Oncologia, Faculdade de Medicina da Universidade de São Paulo, Av. Dr. Arnaldo, 455, Sala 4112, CEP 01246-903, São Paulo, SP, Brazil
Departamento de Psiquiatria, Faculdade de Medicina, Universidade de São Paulo, Rua Dr. Ovídio Pires de Campos, 785, 1◦ andar do IPq, Ala Sul, CEP 05403-010, São Paulo, Brazil
Laboratório de Bioinformática e Bioestatística, Centro Internacional de Pesquisa e Ensino (CIPE) – Hospital AC Camargo, Rua Taguá, 440, CEP 01508-010, São Paulo, Brazil
Instituto Brasileiro de Controle do Câncer, Av. Alcântara Machado 2576, CEP 03102-002, São Paulo, SP, Brazil
r t i c l e i n f o
rticle history:
eceived 1 February 2012
eceived in revised form 3 August 2012





a b s t r a c t
The effects of 1,25 dihydroxyvitamin D3 (1,25D) on breast carcinoma associated ﬁbroblasts (CAFs) are
still unknown. This study aimed to identify genes whose expression was altered after 1,25D treatment
in CAFs and matched adjacent normal mammary associated ﬁbroblasts (NAFs). CAFs and NAFs (from 5
patients) were cultured with or without (control) 1,25D 100nM. Both CAF and NAF expressed vitamin
D receptor (VDR) and 1,25D induction of the genomic pathway was detected through up-regulation of
the target gene CYP24A1. Microarray analysis showed that despite presenting 50% of overlapping genes,
CAFs and NAFs exhibited distinct transcriptional proﬁles after 1,25D treatment (FDR<0.05). Functional
analysis revealed that in CAFs, genes associated with proliferation (NRG1, WNT5A, PDGFC) were down,25 dihydroxyvitamin D3 regulated and those involved in immune modulation (NFKBIA, TREM-1) were up regulated, consistent
with anti tumor activities of 1,25D in breast cancer. In NAFs, a distinct subset of genes was induced
by 1,25D, involved in anti apoptosis, detoxiﬁcation, antibacterial defense system and protection against
oxidative stress, which may limit carcinogenesis. Co-expression network and interactome analysis of
genes commonly regulated by 1,25D in NAFs and CAFs revealed differences in their co-expression values,
ects i
 suggesting that 1,25D eff
. Introduction
Breast carcinomas are complex tissues in which epithelial cells
nteract with their surrounding stromal compartment, which con-
ists of extracellular matrix (ECM) molecules, resident ﬁbroblasts,
nﬂammatory, immune and endothelial cells [1]. Cancer associated
broblasts (CAFs) are the most abundant cell type in breast tumor
troma. CAFs possess an activated phenotype and -smooth mus-
le actin (SMA) is themost commonly usedmarker for identifying
ancer-associated ﬁbroblasts but the tumor microenvironment
lso contains SMA negative ﬁbroblasts. CAFs are also character-
zed by increased expression of S100A4, that marks a population
f ﬁbroblasts distinct from those SMA positive [2]. CAFs secrete
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growth and angiogenic factors as well as a range of chemokines
and ECM proteins [3]. They differ from normal ﬁbroblasts by dis-
playing a distinct gene expression pattern [4]. Importantly, tumor
promoting properties of CAFs appear to be partially independent of
the presence of tumor cells and are maintained in vitro even in the
absence of the epithelial cells [5]. In addition, interactions between
breast cancer associated ﬁbroblasts and mammary epithelial
cells result in alterations in the transcriptional proﬁles of both
cell types [6].
Numerous studies have established that 1,25 dihydroxyvita-
min D3 (1,25D) modulates cell cycle, progression, differentiation
and apoptosis in breast carcinomas via interactionwith the vitamin
D receptor (VDR), but the major focus has been the epithe-
lial compartment (reviewed in [7]). Although various studies of
gene proﬁling have been conducted to elucidate the molecular
mechanisms underlying vitamin D3 effects in breast carcinoma
epithelial cells [8], there are few studies addressing the effects
Open access under the Elsevier OA license.of 1,25D in stromal cells. Response of ﬁbroblasts to the hormone
has been carried out in mesenchymal multipotent cells in culture
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In the current study we have established primary ﬁbroblast cul-
ures isolated from breast carcinomas (CAFs) and paired adjacent
ormal tissue (normal tissue associated ﬁbroblasts, NAFs) and used
icroarrays to investigate the differential effects of 1,25D on gene
xpression proﬁles of each group of ﬁbroblasts. Identiﬁcation of
,25D target genes in these cells may provide a starting point for a
etter understanding of the molecular mechanisms involved in the
,25D effects on breast cancer microenvironment.
. Patients, materials and methods
.1. Patients
Breast tissue specimens were obtained from ﬁve patients
ndergoing surgery for breast carcinoma. Mean age of the
atients was 53.3±10.7 years, all were post-menopausal. Patients
ere diagnosed with invasive ductal carcinoma (IDC) conﬁrmed
istopathologically, clinically staged as II or III. Tumorswere classi-
ed as ER and PR negative, HER-2 positive. None of the patients had
eceivedpreoperative chemotherapy.All patientswereoperatedon
nstituto Brasileiro de Controle do Câncer, IBCC, São Paulo, Brazil.
his study was approved by the Institutional Ethics Committee and
ritten informed consent was obtained from all participants, after
ull explanation of the purpose and nature of all procedures used.
.2. Tissue samples and primary cell culture
Fibroblasts associated to human breast carcinoma were
btained from tissue samples from patients diagnosed with pri-
ary ductal invasive breast cancer tumors (CAF) or isolated from
ormal areas of the same carcinomas (NAF). H&E-stained, frozen
istological sections were prepared from each tissue sample to
onﬁrm malignancy or morphologically normal epithelial tissue.
fter adipose tissue removal, tissue was minced (1–4mm3) into
ieces in PBS (Na2HPO4 10mM, NaCl 1.37mM, KCl 27mM, KH2PO4
mM; Life Technologies, Grand Island, NY, USA), under sterile con-
itions. A total of 10–15 fragments were obtained for each group
f ﬁbroblasts and transferred to 25 cm2 culture ﬂasks and covered
ith Dulbecco’s Modiﬁed Eagle Medium (DMEM; Life Technolo-
ies), 20% FBS (Life Technologies), 100g/ml ampicillin, 100g/ml
treptomycin, 2.5g/ml Fungizone and maintained at 37 ◦C in a
umidiﬁed atmosphere containing 5% CO2. Outgrowth of cells was
ecorded after 10–20 days andmediumwas renewed once or twice
week thereafter. After ﬁbroblastmigration, tissue fragmentswere
emoved and cells were passaged by mild trypsinization with
rypsin0.5% (Life Technologies), andﬁbroblastoid cellswere seeded
nto new culture ﬂasks containing the same medium. After three
ell passages, morphologically homogeneous cultures containing
nlyﬁbroblastoid cellswereobtained.At this stagenomacrophages
ere left. Absence of macrophages and endothelial cells was con-
rmedusinghumananti-CD31andCD163 [6,15]. All CAFs andNAFs
sed were from passages 4 to 6.
.3. Characterization of ﬁbroblasts
Primary cultures of breast cancer associated ﬁbroblasts and
ormal adjacent ﬁbroblasts were characterized by immunoﬂuo-
escence. Brieﬂy, cells in early passages (passage 3) were plated
n circular slides (Ø13mm, Glasscyto, Bioslide Technology, Wal-
ut, CA, USA) and incubated with human anti-vimentin (clone
im 3b4), human anti-smooth muscle actin (clone M0635), human
nti-S100A4 (clone A5114), human anti-pancytokeratin (clones
E1/AE3) and human anti-CD31 (clone JC70A), all antibodies from
ako Corporation (Carpinteria, CA, USA) and human anti-CD163
clone 10D6) fromVector Laboratories (Burlingame, CA, USA). After
hat, cells were incubated with the secondary antibody (Alexary & Molecular Biology 133 (2013) 12–24 13
Fluor 488 anti-rabbit or mouse IgG (Life Technologies) diluted
in PBS. Immunoﬂuorescence was also performed to verify the
presence of vitamin D receptors. Anti-VDR (clone 9A7, Afﬁnity
Bioreagents, Rockford, IL, USA) was used as primary antibody and
FITC-conjugated anti-mouse IgG (Sigma–Aldrich, St. Louis, MO,
USA) as second antibody. The cell analysis was performed using a
Zeiss Axioplan microscope (Carl Zeiss; Jena, Thüringen, Germany).
2.4. Cell treatment
CAFs and NAFs were plated in 75 cm2 culture ﬂasks (5×104
cells per ﬂask, TPP – Techno Plastic Products AG, Trasadigen,
Switzerland) and grown until cells reached 70% conﬂuence. At this
point, cells were treated with DMEM containing 0.5 or 100nM
1,25D (cat. no. 679101, Merck, Darmstadt, Germany) or vehicle
(0.1% ethanol) for 24h.
2.5. Microarray analysis
Total RNA was isolated and puriﬁed using TRIzol® reagent
(Life Technologies) and RNeasy Mini Kit (Qiagen, Valencia, CA,
USA), respectively, according to the manufacturers’ protocols. RNA
integrity was veriﬁed in a Bioanalyzer 2100 (Agilent Technologies,
Santa Clara, CA, USA) and only samples with RNA integrity number
>7 were considered. Beginning with 5g total RNA, a one-round
linear ampliﬁcationwas carriedout according to anAffymetrix pro-
tocol (One Cycle Target Labeling Kit, Affymetrix, Santa Clara, USA).
Afterwards, biotin-labeled cRNA was reverse transcribed using IVT
labeling kit (Affymetrix) and 15g of biotinylated fragmented
aRNA was hybridized onto the Human Genome U133 Plus 2.0
GeneChip. The transcript levels in each samplewere determined by
using the Affymetrix HU133 plus 2.0 GeneChip (Affymetrix, 54,210
probe sets covering over 47,000 transcripts and splice variants).
Hybridized GeneChips were scanned using Affymetrix GeneChip
Scanner 3000 and after visual inspection, raw data were saved into
CEL ﬁles.
The quality of microarray images from individual GeneChips
and the expression distribution at the probe set level between
GeneChips were inspected using Affymetrix GeneChip Operating
Software (GCOS). All of the GeneChips presented high quality and
were used for subsequent analysis.
Background correction, normalization and summarization
of raw data (CEL ﬁles) were performed using the Robust
Multi-Array Average (RMA) method available on R package
(http://www.R-project.org),with the “Affy” library of Bioconductor
Package (http://www.bioconductor.org).
2.6. Statistical analysis of microarray data
First of all, ﬁltering was set to select 30% of genes with the
highest standard deviation. Comparisons of expression levels were
performed using MeV (MultiExperiment Viewer, version 4.5.1)
software.Differentially expressed transcripts after 1,25D treatment
(control vs 1,25D treated) were identiﬁed using the Signiﬁcance
Analysis of Microarray program (SAM, version 3.02). Data for each
comparison were analyzed using a two class, paired analysis with
1000 permutations. For each transcript SAM uses permutation of
the data to identify a False Discovery Rate (FDR) that balances type I
and type II statistical error rates. Signiﬁcance fordifferential expres-
sion due to 1,25D treatment was determined at the 5% FDR. To
identify and visualize biological processes that were enriched due
to 1,25(OH)2D treatment, differentially expressed genes were sub-
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.7. Quantitative real time RT-PCR
Reverse transcription was performed using 3g of total
NA, Oligo dT(12–18) and SuperscriptTM III Reverse Transcrip-
ase (Life Technologies). Primers were designed for different
xons to avoid ampliﬁcation of genomic DNA using Primer-Blast
oftware (http://www.ncbi.nlm.nih.gov/tools/primer-blast/), and
ynthesized by IDT (Integrated DNA Technologies, Coralville, IA,
SA).
Quantitative RT-PCRs were performed using the ABI PrismTM
500 Sequence Detection System. RT-PCRs were carried out using
YBR® Green PCR Power MasterMix using the following program:
0min at 95 ◦C for the initial denaturing, followed by 40 cycles
t 95 ◦C for 15 s and 60 ◦C for 1min. The efﬁciency of each pair of
rimerswas calculatedusing standard curvedilutions (asdescribed
n the Life Technologies protocols). The duplicate average values
ere used for quantiﬁcation and the relative expression of genes
f interest was normalized to that of GAPDH. Gene expression in
ach treated sample was then compared with expression in ﬁbro-
lasts from control samples. Relative gene expression between
ample groups was calculated employing the efﬁciency-corrected
quation. We generated changes in gene expression values of each
reated sample by comparing it with the respective control sample.
tatistical analyses were carried out using t-test.
.8. Co-expression network
We searched for pairs of genes whose co-expression had
hanged and the network was constructed based on all possible
ombinations starting from the 69 commonly altered genes by
,25D. Pearson correlation coefﬁcient (PCC) between pairs of genes
as calculated independently for CAF and NAF [16]. Differences
etween the correlations in the CAF and NAF groups were ranked
or gene pairs. Pairswith absolute differences greater than 1.5were
elected. The idea was to select pairs of genes that have changed
heir co-expressionbetweenCAFsandNAFs.Dataanalysis andvisu-
lization were conducted by Cytoscape software (version 2.8.0;
ww.cytoscape.org).
.9. Network construction
Interaction network analysis was carried out for the 69 genes
ommonly altered in both normal and tumor associated ﬁbro-
lasts after 1,25D treatment by querying three human interactome
atabases (HPRD, MINT and IntAct) [17–19]. We overlaid the
xpression values of each gene on its corresponding protein
nd we constructed a protein–protein interaction network with
hose genes that were mapped in the databases and their direct
artners. To identify broker and bridge genes in network, a pre-
iously published algorithm [20] was implemented using the site
ttp://bioinfo.lbhc.hcancer.org.br/interactomegraph/, a free web
ool to improve the interactome database analysis. Brokers are
enes that connect many proteins that would not be connected
therwise. Bridges are nodes that have few links but connect com-
unities, i.e., very connected groups. We considered as bridge
enes the 2% oneswith higher bridging centrality values and the 2%
nes with higher brokering values were considered broker genes.
e used the top 2% more connected genes to select the hubs.
After construction of the interactome using as our “seed” the
forementioned 69 genes, we searched for pairs of connected
enes present in the microarray. Using the expression values of the
icroarray, the Pearson correlation coefﬁcient (PCC) between pairs
f genes was calculated independently for CAFs and NAFs [16]. Dif-
erences between the correlations in the CAF and NAF groups werery & Molecular Biology 133 (2013) 12–24
ranked for gene pairs. We selected ranked pairs with difference
greater then 1.5.
3. Results
At ﬁrst, to characterize the primary culture cell population,
immunoﬂuorescenceassays to recognize speciﬁc cell antigenswere
performed using cell culture at passage 4. Cell monolayers were
negative for pan-cytokeratin, CD31 (Fig. 1A) and CD163 (data not
shown) and stained uniformly for vimentin (Fig. 1B) conﬁrming the
stromal origin of cells and absence of contaminating endothelial,
epithelial or macrophage cells. Expression of -SMA was detected
in both CAFs andNAFs, however, with some variability among indi-
vidual donors and the percentage of positive cells was generally
higher in CAFs, which often take on the appearance of an activated
or myoﬁbroblastic phenotype (Fig. 1A). The -SMA expression by
NAFs may arise during cell culture conditions as previously sug-
gested [21 and references therein]. S100A4, which marks a distinct
population of ﬁbroblasts than -SMA positive ﬁbroblasts [2], was
detected in CAFs as well as in NAFs, but with a higher proportion
of positive cells in CAFs (Fig. 1A).
We next determined the presence of vitamin D receptor in
CAFs and NAFs. Immunoﬂuorescence analysis through confocal
microscopy revealed the presence of VDR in all ﬁve CAF popula-
tion, with predominant localization in the nucleus rather than in
the cytoplasm. Similar results were found in NAFs (Fig. 1C).
The starting point of this work was the comparison of
gene expression patterns from CAF-untreated controls and NAF-
untreated controls, as there are reports indicating differences
between them [22]. Supplementary Table 1 summarizes the
expression differences, assuming a 1.4-fold difference cutoff
between CAFs and matched NAFs (CAF/NAF ratio). Gene ontology
categories (biological process) enriched in genes more expressed
in CAFs were cell cycle, protein transport, apoptosis, cell prolif-
eration and carbohydrate metabolic processes and in NAFs were
immune response, lipid metabolic processes, cell differentiation,
cell adhesion and cell proliferation (Supplementary Fig. 1).
We next investigated the ability of 1,25D to differentially reg-
ulate gene expression of CAFs and NAFs, and for this analysis two
hormone concentrations were used, 0.5nM, which can be safely
attained in vivo [23] and 100nM, a supra physiological concen-
tration, commonly utilized in experiments in vitro, to investigate
global gene expression in cancer epithelial or mesenchymal cell
lines [7,11].
In CAFs, 1,25D 0.5nM responsiveness was modest, but it was
detected as an induction of the hormone target CYP24A1, whose
expression increased 6.7-fold at 24h as compared to counterpart
controls in the absence of 1,25D. Another 274 genes were induced,
with fold changes ranging from 1.13 to 2.46, including 11 genes,
whose expression was further analyzed by RT-PCR, in a techni-
cal validation assay. In general there was qualitative agreement
between the two techniques with all genes showing similar trends,
including two (TGF2 and CYP24) which were conﬁrmed as more
expressed in 1,25D treated ﬁbroblasts. A possible explanation for
the lack of statistical signiﬁcance for the other PCR determina-
tions might be the small fold changes in gene expression (data not
shown).
We then decided to use a pharmacological concentration
(100nM), commonlyused to investigate1,25Deffects in cell culture
assays. Adopting a 5% FDR cut-off we identiﬁed 126 and 123 genes
differentially expressed in NAFs and CAFs 1,25D treated, respec-
tively, as compared with their untreated controls. A Venn diagram
detected 69 overlapped genes regulated by 1,25D 100nM in both
CAFs and NAFs, among which, only 3 were down regulated (Fig. 2,
Supplementary Tables 2–4). Fifty four genes were exclusively
L.T. Campos et al. / Journal of Steroid Biochemistry & Molecular Biology 133 (2013) 12–24 15
Fig. 1. Characterization of ﬁbroblast primary culture isolated from breast carcinoma tissue sample (CAF) and from paired normal adjacent breast tissue (NAF). Immunoﬂuo-
rescence analysis followed by confocal microscopy in representative cases (A) showed uniformly positive staining for -SMA and negative staining for pan-cytokeratin and
C Fs. (B)















iD31, while S100A4 positive stained cell frequency was higher in CAFs than in NA
ells was more concentrated in the nucleus than in the cytoplasm (arrows indicat
uclear marker (blue ﬂuorescence) in all experiments. Scale bar: 50m.
odulated in CAFs (but not in NAFs): 27 up- and 27 down-
egulated. Speciﬁcally in NAFs (but not in CAFs) 1,25D3 treatment
p regulated 55 and down regulated other two genes.
Among genes speciﬁcally regulated in CAFs, prolifera-
ion/apoptosis related processes were over represented. In
hese ﬁbroblasts, out of 27 genes down regulated by 1,25D, several
ere related to this particular function (ADK, SOX9, WNT5A, PDGFC,
RG1, F2R) except for NFKappaBIA (an inhibitor of NF-KappaB),
hich was up-regulated. Another functional categories enriched
fter 1,25D treatment included genes associated either with
esponse to wounding, like TREM1, WNT5A, F2RL2 (PAR-3), F2R
PAR-1), or with extracellular matrix and intracellular transport
Table 1).
In NAFs, genes exclusively modulated by 1,25D were involved
n multiple cellular processes. Several up-regulated genes were
nvolved in negative regulation of proliferation or in anti-apoptosisVimentin expression was restricted to cytoplasm and (C) VDR expression in both
e representative cell VDR expression in nuclei and cytoplasm): DAPI was used as
(out of 11 genes, 7 were anti-apoptotic) such as VEGFA, TCF7L2,
GCLC, IL7R1, NCAM1, SERPINB9 and CNKSR2. A number of up regu-
lated genes fall in the category of immune response (TLR4, PRDM1,
IL7R, PEL12, LRIG1, BMP6). However, genes associated with other
biologic processes such as transmembrane transport and regu-
lation of transport (KCNK3, SLC4A7, RAB8B1, ATP2B1), xenobiotic
metabolic process (GLYAT, GCLC and CYP3A5), and ATP catabolic
process (ABCB4, ABCA6, ABCA8) were also up regulated by 1,25D
in NAFs (Table 2).
Among overlapping genes altered by 1,25D in CAFs as well in
NAFs (n=69), several functional groupswere identiﬁed: geneswith
roles in proliferation and apoptosis, immune response and inﬂam-
mation, lipid metabolism, ras family, cell adhesion and regulation
of cell transduction were the most represented. The range of fold
regulation of gene expression varied from 1.71 to 5.54, with small
differences in fold changevaluesbetweenNAFsandCAFs, exception












































1ig. 2. Venn diagram showing the number of genes differentially expressed in C
ifferentially expressed in CAFs and NAFs modulated by 1,25D 100nM vs controls.
ade forCYP24A1,which exhibitedby far thehighest up-regulation
f all (516-fold in CAFs and 299-fold in NAFs) (Table 3).
Although the gene expressionproﬁles varied considerablywhen
omparing control CAFs and NAFs (Supplementary Table 1), this
et of genes did not overlap signiﬁcantly with the set of differen-
ially expressedgenes following1,25D treatment, except for a small
umber of genes. However, comparing the functional categories of
hese two gene sets we could observe that some similar functions
ere present in both of them (Supplementary Fig. 1 and Tables
–3).
Comparing 1,25D transcriptional effects speciﬁcally in NAFs
nd genes differentially expressed in NAFs vs CAFs, only 5 genes
ere found, most of them (n=4) more expressed in NAFs and up-
egulatedby thehormone:ACSL3,ATP2B1, FHOD3,VEGFA, andone,
ess expressed in NAFs (vs CAFs) and up-regulated by 1,25D.
Among overlapping genes regulated by1,25D in CAFs and genes
ifferentially expressed between CAFs vs NAFs the scenario was
ore complex: 7 genes more expressed in CAFs (than NAFs) were
own-regulated by 1,25D in CAFs (ADK, AMIGO2, CCDC99, E2F7,
AS2, MYBL1, PDGFC); 5 genes less expressed in CAFs (vs NAF)
ere up-regulated by 1,25D in CAFs (CCDC85B, CSF1, MAN1C1,
TSS1, SULF2). Another two genes were regulated by 1,25D in
AFs: GALNT12 (less expressed in CAFs and down regulated by
,25D) and SOD2 (more expressed in CAFs and up-regulated by
,25D). In addition, six genes were up-regulated by 1,25D in both
AFs and NAFs, all of them considered less expressed in CAFs (vs
AFs): MALL, NLRP1, OSR1, OSR2, TGFB2, TMEM119. Hence, from
0 genes differentially expressed in CAFs (vs NAFs) and modulated
y 1,25D, 18 were regulated by the hormone toward a closer sim-
larity with NAFs. An example is HAS2 (hyaluronan synthase 2)
hich plays a critical role in the development of a pro metastatic
icroenvironment [24]. HAS2 expression was 6.97-fold higher in
AFs (vs NAFs) and was reduced in CAFs after 1,25D treatment. On
he other hand, IL8whichwasmore expressed in CAFs than inNAFs
resenting a fold of 37.4 as compared to the values found in NAFs
Supplementary Table 1) did not appear as differentially expressed
n the list ofCAFs treatedwith1,25Dvs respective in treatedcontrol.
ur interpretation of the above comparison is that the expression
evels of the genes differentially expressed between control CAFs
nd NAFs may be differentially affected after 1,25D treatment but
he resulting expression levels did not reach signiﬁcant differences.
ontrariwise, other genes whose basal levels did not signiﬁcantly
iffer between the two control cell types havebeen changedgreatly
fter 1,25D treatment.
Nineteen genes (with the highest fold changes induced by
,25D) were selected for technical validation assays throughd NAFs after 1,25D treatment. Using microarray analysis we determinate genes
g these genes, 69 were commonly regulated by 1,25D in both CAFs and NAFs.
quantitative real time RT-PCR. These experiments conﬁrmed 84%
of the gene expression changes were induced in CAFs or NAFs by
1,25D. The results are visualized in Supplementary Table 5 and
indicate that 1,25D modulates the expression of genes involved in
diverse biological processes, such asmetabolism (CYP24A1,CYP3A5,
IDH2, GJA1), steroidal metabolism (SULT1C2), cell proliferation, cell
cycle and transduction signals (G0S2, IGF1, MAPK13, FGF9, NRG1,
TGFB2) as well as inﬂammatory and immune responses (CD14,
CSF2RB, IL7R, TLR4) and ATP catabolic process (ABCB4).
As a biological validation procedure we compared 1,25D effects
shared by ﬁbroblasts (CAFs and NAFs) with breast cancer fresh
tissue slices exposed in vitro to the hormone. All samples were
from post-menopausal patients with invasive ductal carcinoma (2
of themERpositiveand2HER-2positive) and tumorsliceswerecul-
tured in the presence or absence of 1,25D 100nM for 24h. We have
used this tissue model before and shown that VDR is present and
that the genomic pathway is active, detected as CYP24A1 induc-
tion [25]. Comparing 1,25D effects in CAFs and NAFs with breast
cancer slices we identiﬁed 24 genes commonly regulated, 22 of
them up-regulated by 1,25D. Genes up-regulated in both CAFs
and NAFs and breast cancer tissue slices included: APBB1IP, CD14,
CILP, CLMN, CYP24A1, DPP4, EFTUD1, FAM20C, FOXF1, G0S2, GRK5,
IL1RL1, RGNEF, SERPINB1, SLC1A1, THBD [26].
To better investigate ﬁndings related to the genes commonly
altered by 1,25D in both NAFs and CAFs, we decided to use two
approaches.
We ﬁrst constructed a gene–gene network (co-expression net-
work) using the values of Pearson correlation between pairs of
genes, based on all possible combinations of the 69 commonly
altered (in both CAFs and NAFs) genes by 1,25D. Differences
between the correlations in either NAF or CAF groups were ranked
for gene pairs. Pairs with high absolute differences indicated that
the two correlations were in opposite sides of zero and closer to 1
and−1orviceversa respectively. By restricting theanalysis to those
with absolute differences greater than 1.5we selected a group of 38
pairs of genes (Supplementary Table 6). It is important to note we
found changes in the correlations of the expression levels of genes
between NAF and CAF groups.
Using the dynamic structure of the human protein interaction
network (interactome) it has recently been shown that genes that
are not differently expressed may indicate relevant differences
between tumor samples and controls [27].Using the set of genes commonly differentially expressed in
1,25D treated CAFs and NAFs as compared with respective controls
(n=69) we next searched for interactions among those genes and
their neighbors in the human interactome [28] (Fig. 3). To explore
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Table 1
Genes with expression exclusively regulated in CAFs by 1,25D.
Gene symbol Gene description Fold change
Cell proliferation
SOD2a Superoxide dismutase 2, mitochondrial 9.52
FGF9 Fibroblast growth factor 9 (glia-activating factor) 2.77
EGFR Epidermal growth factor receptor 1.96
CSF1 Colony stimulating factor 1 (macrophage) 1.84
NFKBIA Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 1.82
PTCH1 Patched 1 1.61
PDGFCa Platelet derived growth factor C −1.91
WNT5Aa Wingless-type MMTV integration site family, member 5A −2.22
SOX9 SRY (sex determining region Y)-box 9 −2.23
E2F7 E2F transcription factor 7 −2.33
ADK Adenosine kinase −2.35
F2R Coagulation factor II (thrombin) receptor −2.80
NRG1 Neuregulin 1 −3.23
MAPK cascade
FGF9 Fibroblast growth factor 9 (glia-activating factor) 2.77
EGFR Epidermal growth factor receptor 1.96
WNT5A Wingless-type MMTV integration site family, member 5A −2.22
OXTR Oxytocin receptor −2.36
RGS4 Regulator of G-protein signaling 4 −2.38
F2R Coagulation factor II (thrombin) receptor −2.80
NRG1 Neuregulin 1 −3.23
Apoptosis
SOD2b Superoxide dismutase 2, mitochondrial 9.52
EGFR Epidermal growth factor receptor 1.96
DUSP1b Dual speciﬁcity phosphatase 1 1.84
NFKBIAb Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 1.82
TWIST2b Twist homolog 2 (Drosophila) 1.75
AMIGO2b Adhesion molecule with Ig-like domain 2 −1.88
PHF17 PHD ﬁnger protein 17 −2.05
SERPINB2b Serpin peptidase inhibitor, clade B (ovalbumin), member 2 −2.06
FAM176A Family with sequence similarity 176, member A −2.12
WNT5A Wingless-type MMTV integration site family, member 5A −2.22
SOX9 SRY (sex determining region Y)-box 9 −2.23
F2R Coagulation factor II (thrombin) receptor −2.80
NRG1b Neuregulin 1 −3.23
Response to vitamin
DUSP1 Dual speciﬁcity phosphatase 1 1.84
PTCH1 Patched 1 1.61
WNT5A Wingless-type MMTV integration site family, member 5A −2.22
SOX9 SRY (sex determining region Y)-box 9 −2.23
Extracellular structure organization
OXTR Oxytocin receptor 2.36
LOX Lysyl oxidase 1.85
WNT5A Wingless-type MMTV integration site family, member 5A −2.22
F2R Coagulation factor II (thrombin) receptor −2.80
NRG1 Neuregulin 1 −3.23
Regulation of cell communication
FGF9 Fibroblast growth factor 9 (glia-activating factor) 2.77
OXTR Oxytocin receptor 2.36
EGFR Epidermal growth factor receptor 1.96
CSF1 Colony stimulating factor 1 (macrophage) 1.84
NFKBIA Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 1.82
RGS4 Regulator of G-protein signaling 4 −2.06
WNT5A Wingless-type MMTV integration site family, member 5A −2.22
RIMS1 Regulating synaptic membrane exocytosis 1 −2.45
F2R Coagulation factor II (thrombin) receptor −2.80
NRG1 Neuregulin 1 −3.23
Intracellular transport
FGF9 Fibroblast growth factor 9 (glia-activating factor) 2.77
EGFR Epidermal growth factor receptor 1.96
NFKBIA Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 1.82
PPP1R3C Protein phosphatase 1, regulatory (inhibitor) subunit 3C −2.19
RIMS1 Regulating synaptic membrane exocytosis 1 −2.45
F2R Coagulation factor II (thrombin) receptor −2.80
Response to wounding
SOD2 Superoxide dismutase 2, mitochondrial 9.52
TREM1 Triggering receptor expressed on myeloid cells 1 4.11
LOX Lysyl oxidase 1.85
SERPINB2 Serpin peptidase inhibitor, clade B (ovalbumin), member 2 −2.06
WNT5A Wingless-type MMTV integration site family, member 5A −2.22
F2RL2 Coagulation factor II (thrombin) receptor-like 2 −2.34
F2R Coagulation factor II (thrombin) receptor −2.80
NRG1 Neuregulin 1 −3.23
a Genes involved with regulation of ﬁbroblast proliferation.
b Genes involved with anti-apoptosis.
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Table 2
Genes with expression exclusively regulated in NAFs by 1,25D.
Gene symbol Gene description Fold change
Cell proliferation
AKR1B1a ATPase, Ca2+ transporting, plasma membrane 1 1.60
ATP2B1b Aldo–keto reductase family 1, member B1 (aldose reductase) 1.94
BCAT1 Branched chain amino-acid transaminase 1, cytosolic 2.50
CRIP1 Cysteine-rich protein 1 (intestinal) 3.44
FIGFa c-fos induced growth factor (vascular endothelial growth factor D) 1.90
GJA1b Gap junction protein, alpha 1, 43kDa 1.71
LRRC17 Leucine rich repeat containing 17 1.53
NFIBb Nuclear factor I/B 2.93
PRDM1b PR domain containing 1, with ZNF domain 2.00
Apoptosis
ABCB1b ATP-binding cassette, sub-family B (MDR/TAP), member 1 1.90
CNKSR2b Connector enhancer of kinase suppressor of Ras 2 1.94
FEM1Ba fem-1 homolog b (C. elegans) 2.30
GCLCb Glutamate-cysteine ligase, catalytic subunit 2.20
IL7Ra Interleukin 7 receptor 2.60
NCAM1b Neural cell adhesion molecule 1 1.85
SEMA3B Semaphorin 3B 1.82
SERPINB9b Serpin peptidase inhibitor, clade B (ovalbumin), member 9 1.80
TCF7L2b Toll-like receptor 4 2.20
TLR4a Transcription factor 7-like 2 (T-cell speciﬁc, HMG-box) 2.90
VEGFAb Vascular endothelial growth factor A 1.92
Immune system process
BMP6 Bone morphogenetic protein 6 1.70
FZD8 Frizzled homolog 8 (Drosophila) 1.60
IL7R Interleukin 7 receptor 2.60
LRIG1 Leucine rich repeat containing 17 2.22
LRRC17 Leucine-rich repeats and immunoglobulin-like domains 1 1.58
PELI2 Pellino homolog 2 (Drosophila) 1.80
PODXL Podocalyxin-like 2.94
PRDM1 PR domain containing 1, with ZNF domain 1.99
TLR4 Toll-like receptor 4 1.70
Cellular transport
Transmembrane transport
ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 1.90
ABCB4 ATP-binding cassette, sub-family B (MDR/TAP), member 4 2.20
ATP2B1 ATPase, Ca2+ transporting, plasma membrane 1 2.00
KCNK3 Potassium channel, subfamily K, member 3 5.60
SLC4A7 Solute carrier family 4, sodium bicarbonate cotransporter, member 7 1.65
STEAP1 Six transmembrane epithelial antigen of the prostate 1 1.70
TMEM16D Anoctamin 4 1.90
Regulation of transport
GJA1 Gap junction protein, alpha 1, 43kDa 1.70
KCNK3 Potassium channel, subfamily K, member 3 5.60
RAB8B RAB8B, member RAS oncogene family 2.06
TCF7L2 Transcription factor 7-like 2 (T-cell speciﬁc, HMG-box) 1.60
TLR4 Toll-like receptor 4 1.70
Cell–cell adhesion
CDH6 Cadherin 6, type 2, K-cadherin (fetal kidney) 1.70
NCAM1 Neural cell adhesion molecule 1 1.85
PLEKHA7 Pleckstrin homology domain containing, family A member 7 3.35
PODXL Podocalyxin-like 2.94
Regulation of metabolic process
BMP6 Bone morphogenetic protein 6 1.70
FZD8 Frizzled homolog 8 (Drosophila) 1.60
GCLC Gap junction protein, alpha 1, 43kDa 2.20
GJA1 Glutamate-cysteine ligase, catalytic subunit 1.70
NFIB Nuclear factor I/B 2.98
PRDM1 PR domain containing 1, with ZNF domain 3.00
TCF7L2 Transcription factor 7-like 2 (T-cell speciﬁc, HMG-box) 2.20
TLR4 Toll-like receptor 4 2.90
VEGFA Vascular endothelial growth factor A 1.92
ATP catabolic process
ABCB4 ATP-binding cassette, sub-family B (MDR/TAP), member 4 2.20
ABCA6 ATP-binding cassette, sub-family A (ABC1), member 6 1.94
ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8 2.40
Xenobiotic metabolic process
CYP3A5 Cytochrome P450, family 3, subfamily A, polypeptide 5 4.20
GCLC Glutamate-cysteine ligase, catalytic subunit 2.20
GLYAT Glycine-N-acyltransferase 2.15
a Genes involved with positive regulation of cell proliferation.
b Genes involved with negative regulation of cell proliferation.
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Table 3
Gene expression commonly regulated in CAFs and NAFs by 1,25D.





BCL2 B-cell CLL/lymphoma 2 1.91 2.34
DPP4 Dipeptidyl-peptidase 4 1.77 1.74
EDNRB Endothelin receptor type B 1.97 5.34
FOXF1 Forkhead box F1 3.02 2.33
IGF1 Insulin-like growth factor 1 (somatomedin C) 3.10 3.81
NAMPT Nicotinamide phosphoribosyltransferase 3.15 1.79
OSR1 Odd-skipped related 1 (Drosophila) 3.91 3.63
PDPN Podoplanin 2.72 2.86
TACSTD2 Tumor-associated calcium signal transducer 2 2.37 1.69
TGFB2 Transforming growth factor, beta 2 4.74 5.38
Apoptosis
BCL2 B-cell CLL/lymphoma 2 1.91 2.34
CD14 CD14 molecule 5.54 3.02
DDIT4 DNA-damage-inducible transcript 4 1.77 1.70
EDNRB Endothelin receptor type B 1.97 5.34
IER3 Immediate early response 3 −2.42 −2.36
IGF1 Insulin-like growth factor 1 (somatomedin C) 3.10 3.81
NLRP1 NLR family, pyrin domain containing 1 2.80 2.62
OSR1 Odd-skipped related 1 (Drosophila) 3.91 3.63
RASSF5 Ras association (RalGDS/AF-6) domain family member 5 2.59 2.04
SIX1 SIX homeobox 1 2.02 1.99
SPP1 Secreted phosphoprotein 1 2.26 2.21
TGFB2 Transforming growth factor, beta 2 4.74 5.38
Immune system process
BCL2 B-cell CLL/lymphoma 2 1.91 2.34
CD14 CD14 molecule 5.54 3.02
CD97 CD97 molecule 1.93 1.98
DPP4 Dipeptidyl-peptidase 4 1.77 1.71
DUSP10 Dual speciﬁcity phosphatase 10 2.91 1.71
EDNRB Endothelin receptor type B 1.97 5.34
FOXF1 Forkhead box F1 3.02 2.33
GEM GTP binding protein overexpressed in skeletal muscle 1.92 2.25
IL1RL1 Interleukin 1 receptor-like 1 3.48 3.85
PAG1 Phosphoprotein associated with glycosphingolipid microdomains 1 1.55 3.83
SIX1 SIX homeobox 1 2.02 1.99
TGFB2 Transforming growth factor, beta 2 4.74 5.38
THBD Thrombomodulin 4.74 5.38
ZFP36 Zinc ﬁnger protein 36, C3H type, homolog (mouse) 2.60 2.05
Response to wounding
APBB1IP Amyloid beta (A4) precursor protein-binding, family B, member 1 interacting protein 1.95 2.01
BCL2 B-cell CLL/lymphoma 2 1.91 2.34
CD14 CD14 molecule 5.54 3.02
CD97 CD97 molecule 1.93 1.98
DUSP10 Dual speciﬁcity phosphatase 10 2.91 1.71
FOXF1 Forkhead box F1 3.02 2.33
IGF1 Insulin-like growth factor 1 (somatomedin C) 3.10 3.81
IL1RL1 Interleukin 1 receptor-like 1 3.48 3.85
NINJ1 Ninjurin 1 2.05 2.02
PDPN Podoplanin 2.72 2.86
SPP1 Secreted phosphoprotein 1 2.26 2.21
TGFB2 Transforming growth factor, beta 2 4.74 5.38
THBD Thrombomodulin 5.61 3.41
ZFP36 Zinc ﬁnger protein 36, C3H type, homolog (mouse) 2.6 2.05
Actin cytoskeleton organization
AVIL Advillin 3.82 2.78
BCL2 B-cell CLL/lymphoma 2 1.91 2.34
RHOJ Ras homolog gene family, member J 1.95 1.96
RHOU Ras homolog gene family, member U 3.02 4.80
Cell adhesion
BCL2 B-cell CLL/lymphoma 2 1.91 2.34
CD97 CD97 molecule 1.93 1.98
DPP4 Dipeptidyl-peptidase 4 1.77 1.71
FOXF1 Forkhead box F1 3.02 2.33
LGALS9 Lectin, galactoside-binding, soluble, 9 2.72 1.98
NID2 Nidogen 2 (osteonidogen) 3.29 3.13
NINJ1 Ninjurin 1 2.05 2.02
PDPN Podoplanin 2.72 2.86
SPP1 Secreted phosphoprotein 1 2.26 2.21
TGFB2 Transforming growth factor, beta 2 4.74 5.38
Ras protein signal transduction
IGF1 Insulin-like growth factor 1 (somatomedin C) 3.10 3.81
MAPK13 MITOGEN-activated protein kinase 13 4.53 3.52
PLD1 phospholipase D1, phosphatidylcholine-speciﬁc 1.61 2.66
RGNEF 190kDa guanine nucleotide exchange factor 2.25 2.16
RHOJ Ras homolog gene family, member J 1.95 1.96
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RHOU Ras homolog gene family, member U 3.02 4.80
Regulation of cell transduction
CILP Cartilage intermediate layer protein, nucleotide pyrophosphohydrolase 5.51 5.39
CYP26B1 Cytochrome P450, family 26, subfamily B, polypeptide 1 4.21 2.41
DDIT4 DNA-damage-inducible transcript 4 1.77 1.70
DUSP10 Dual speciﬁcity phosphatase 10 2.91 1.71
GRK5 G protein-coupled receptor kinase 5 1.95 2.14
IGF1 Insulin-like growth factor 1 (somatomedin C) 3.10 3.81
IL1RL1 Interleukin 1 receptor-like 1 3.48 3.85
LGALS9 Lectin, galactoside-binding, soluble, 9 2.72 1.98
RGNEF 190kDa guanine nucleotide exchange factor 2.25 2.16
RHOJ Ras homolog gene family, member J 1.95 1.96
RHOU Ras homolog gene family, member U 3.02 4.8
TGFB2 Transforming growth factor, beta 2 4.74 5.38
Lipid metabolic process
AKR1C1 Aldo–keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha
(3-alpha)-hydroxysteroid dehydrogenase)
1.84 2.00
AKR1C2 Aldo–keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid
binding protein; 3-alpha hydroxysteroid dehydrogenase, type III)
1.98 1.79
AKR1C3 Aldo–keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase,
type II)
1.39 1.66
CYP24A1 Cytochrome P450, family 24, subfamily A, polypeptide 1 512.61 298.69
CYP26B1 Cytochrome P450, family 26, subfamily B, polypeptide 1 4.21 2.41
GDPD5 Glycerophosphodiester phosphodiesterase domain containing 5 1.88 2.12



































PLD1 Phospholipase D1, phosphatidylcholine-speciﬁc
SERINC2 Serine incorporator 2
he most important genes we searched for hubs, broker and bridge
enes in the network.Wehave considered bridge genes the 2%ones
ith high bridging centrality values and broker genes the 2% ones
ith high brokering values. Hubs were the 2% nodes more con-
ected with ≥54 partners. The best 2% broker genes were MAPK13,
RB2 and BCL2 which were also hubs. The breast bridge genes were
SEA,ADA,GLGC.Wealso searched for genes connectedby the inter-
ctome (presented in Fig. 3) in the microarray platform and we
ound 381 genes. We ﬁnally constructed the interactions using the
onnection values as the Pearson correlation between gene pairs in
ach NAF and CAF groups treated with 1,25D. Differences between
he correlations in the CAF and NAF groups were ranked for gene
airs. By restricting genepairs inwhich the absolute correlationdif-
erences were greater than 1.5 we selected a group of 73 gene pairs
Supplementary Table 7) (0.3% of all pairs selected). Fig. 4 shows the
hanges in the correlation (positive or negative vice versa) of the
xpression level of genes coding for interacting proteins between
he NAF and CAF groups.
. Discussion
Ourmicroarraydata revealed that thegenomicpathway is active
n CAFs as well as in NAFs, as VDR protein was detected in both of
hem and the target gene CYP24A1 was highly induced upon 1,25D
reatment. In accordance, VDR expression was previously reported
n prostate carcinoma associated ﬁbroblasts [14]. CYP24A1 fold
nduction was higher in CAFs than in NAFs, suggesting a less inten-
ive response to the hormone in the tumor microenvironment as
,25D may be metabolized to a less active form [29].
Although mammary ﬁbroblasts (CAFs and NAFs) may share a
ommontranscriptional response to1,25D treatment, an individual
esponse was also characterized. The 1,25D responsive signature
peciﬁc to CAFs reﬂected an antiproliferative effect of 1,25D by
own regulation of several genes with proliferative functions. One
xample is neuregulin (NRG1) that represents the largest sub-
lass of ligands of the EGF family that activates HER-2 [30]. Other
enes down regulated included WNT5A, SOX9, PDGFC, F2RL2 (PAR-
) and F2R (PAR-1). Results in pulmonary ﬁbroblasts supported2.72 2.86
1.61 2.66
2.80 2.93
a role for Wnt5a in regulating ﬁbroblast proliferation and sur-
vival [31]. SOX9, a high mobility group box transcription factor
drives growth factor signal transduction [32] and the two genes
associated to cellular effects of thrombin (a multifunctional serine
protease), F2RL2 and F2R may mediate thrombin induced prolifer-
ation, migration and matrix biosynthesis [33], suggesting that the
antiproliferative actions of 1,25D are modulated through several
different pathways. We also observed modulation of several genes
associated with response to wounding, in accordance with the pro-
posed role of 1,25D in wound healing [34], and reinforcing the
idea that CAFs may exhibit molecular characteristics similar to that
of activated stromal ﬁbroblasts normally associated with wound
healing [5].
On the other hand the hormone induced the up-regulation of
both DUSP1 and NF-KappaBIA. The former encodes a phosphatase
that speciﬁcally inactivates MAPKs and WNT5A while NF-KappaBIA,
an interferon related gene codes for an inhibitor of NF-KappaBIA. In
our comparison of control CAFs vs NAFs we found several genes
regulated by NF-KappaBIA such as IL-8, COX2 and IL-1ˇ, consistent
with data showing that ﬁbroblasts may play a major role in inﬂam-
matory processes by secretion of pro-inﬂammatory cytokines in an
NF-kappaB-dependent manner [35]. 1,25D may exert anti inﬂam-
matory effects by decreasing NF-kappaBIA activation, an effect
previously reported in ﬁbroblasts [9,10].
Additionof 1,25D toNAFs, in contrastwithCAFs, inducedup reg-
ulation of several anti-apoptotic genes thatmay represent effectors
of survival. Our results are in agreementwith Artaza et al. [11], who
described an anti-apoptotic effect of 1,25D in a multipotent mes-
enchymal cell model. We also observed in NAFs an up regulation
of a number of transcripts for proteins controlling immune func-
tions including toll-like receptor 4 (TLR4) and of Pellino-2, one of
the essential components in the TLR4 pathway activations consis-
tent with the anti microbial activity of 1,25D [36]. Some other up
regulated genes appear to be involved in ATP catabolic process
including ATP binding cassette members and enzymes involved in
detoxiﬁcation (GLYAT, CYP3A5, GCLC). GCLC ( glutamylcysteine
synthesis) is a rate limit enzyme, important for glutathione syn-
thesis, a potent antioxidant protein. The protective role of 1,25D
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(AFs and NAFs after 1,25D treatment. Bridge genes are represented by blue diamon
enes present in the list of 69 genes commonly regulated in NAFs and CAFs. The la
hubs).
gainst cellular stress in the breast epithelial cells was recently
iscussed [37] and prior observed in non-transformed prostate
pithelial cell line [38].
Overlapping up regulated genes responding similarly to 1,25D
n NAFs and CAFs, included those reﬂecting an antiprolifera-
ive/apoptotic/differentiation response such as: G0S2 (involved
n adipocyte differentiation), IGF1, TGFˇ2, MAPK13 (p38) and
DIT4 (RDD1), the latter previously found to be down regulated
n cell lines resistant to 1,25D [39]. Our results also identiﬁed
AG1 (phosphoprotein associatedwith glycosphingolipid enriched
icro-domains) as a gene induced by 1,25D, which is involved in
ntimitogenic function, negatively regulating tyrosine kinases [40]
nd a number of genes of the RAS family (RhoU, RASSF5, RGNEF
RIP2), RAB9B, RHOJ) which were also commonly up regulated.broker genes are represented by pink circles, circles with yellow border represent
he circle representing a node, the larger the number of connections this node has
RASSF2AandRASSF5are considered tumoral suppressors [41],RhoU,
a Rho family GTPase regulates cell adhesion [42]. Other genes up
regulated by 1,25D encompass those coding for hormone metab-
olizing enzymes such as AKR1C1, AKR1C2 and AKR1C3, involved
in progesterone metabolism and polycyclic aromatic detoxiﬁca-
tion, which were previously described as present in NAFs and CAFs
[4]. SULT1C2 has been shown to sulfonate estradiol, inactivating
its biological activity, as well as environmental xenobiotics [43].
Enhanced expression of these enzymes by 1,25D may result in
diminished effects of the hormonal milieu on breast carcinoma
epithelial cells, contributing to the beneﬁcial effect of 1,25D. Con-
sistent with an anti-inﬂammatory role of 1,25D, immune response
genes such as CD14, CD97, THBD, IL1RL1, SPP1,DUSP10 (dual speciﬁc
phosphatase 10) and GEM were also up regulated.
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lhe human interactome. Pearson correlation values were calculated for gene pairs.
ore than 1.5-fold comparing NAFs and CAFs treated with 1,25D.
In accordance with other studies investigating 1,25D actions in
arious cellular models, in CAFs and NAFs our data show modula-
ion of several 1,25D targets alreadydescribed, suggesting common
athways, irrespective of cellular types [38,39,44–47]. In agree-
ent, we veriﬁed that many genes were also modulated in breast
ancer tissue slices, containing a mixture of ﬁbroblasts (NAFs and
AFs) and malignant epithelial cells, including CYP24A1, CD14,
PP4, EFTUD1, G0S2, IL1RL1, and THBD.
Although some genes have been commonly differentially
xpressed in NAFs and CAFs treated with 1,25D we could observe
ith the analyses of gene–gene co-expression that the co-
xpression of some of those genes was different in NAFs and CAFs.
or instance the gene hNANOS1 repressed by E-cadherin encodes
protein involved in migration and invasive abilities and its pair
LD1 (phospholipase D1) encodes a protein, which is also involved
n invasion of breast cancer cells [48,49]. The gene pairNANOS1 and
LD1 was positively expressed in CAFs and presented a negative
orrelation in NAFs.
To further explore the relevance of our set of 69 genes we
apped them into the human interactome and we searched for
nteractions among these genes. It is important to note that using
his network approach, we have observed alterations of coexpres-
ion that would not be apparent, looking only to differentially
xpressedgenes, once these connectionsbasedon thehuman inter-
ctome, means real interactions by protein–protein. Genes not
ifferentially expressed by the microarray also presented different
o-expression in this network. This analysis permitted searching
or the most important genes in the network referred as hubs, bro-
ers or bridges genes (Fig. 3). These groups of genes may play an
mportant role in the information ﬂow through the network [50].
enes fromthis network thatweredescribedasbrokers in that they
onnected many proteins may be important genes that are associ-
ted with 1,25D effects on CAFs and NAFs. MAPK13 (p38) is one of
he p38MAPK isoforms which is involved in response to stress [51]
s an example of broker gene.
We ﬁnally constructed the interactions based on the human
nteractome, andwe searched pairs present in themicroarray. Ana-
yzing the connection values as the Pearson correlation betweenwe can observe the diagrams of gene pairs that changed their co-expression value
expressed gene pairs in the CAF and NAF groups, we have identi-
ﬁed gene sets whose concerted expression could distinguish 1,25D
effects on NAFs and CAFs. One example is BCL2 that codes for an
anti apoptotic protein which was differentially expressed at low
levels in the array butwas interconnectedwith other proteins asso-
ciated to apoptosis such as: TP53, PPP2CA (protein phosphatase 2,
implicated in negative control of growth),BCLAF1 (BCL2L associated
transcription factor that induces apoptosis), BLK (protects cell from
virally induced cell death). Correlation of the expression of BCL2
with the expression of these partners was different in NAFs and
CAFs (Fig. 4). These results revealed that measuring the network
modularity that indicated altered organization and information
ﬂow may improve the response to 1,25D.
In conclusion, CAFs and NAFs displayed differences in their pat-
tern of gene expression in response to 1,25D. Even in the group
of overlapped genes we identiﬁed gene pairs displaying differen-
tial expression between CAFs and NAFs suggesting that the effects
of 1,25D on normal ﬁbroblasts are distinct from those triggered in
breast cancer associated ﬁbroblasts.
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